Bruce C Cozadd sold $14M of JAZZ
Chairman & CEO at Jazz Pharmaceuticals plc. 77,500 shares at an average of $177.81, traded Nov 26, 2025, filed Dec 1, 2025.
Score components
- +15RoleDirector
- +25Trade size$13.8M at market
- +5Share of holdings soldSold 16% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193210-25-000011, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 26, 2025 | MOption exercise Ordinary Shares | +76,689 | $123.36 | $9.5M | 470,021 | Dec 1, 2025 |
| Nov 26, 2025 | MOption exercise Ordinary Shares | +811 | $123.36 | $100k | 470,832 | Dec 1, 2025 |
| Nov 26, 2025 | SOpen-market sale Ordinary Shares | -30,487 | $178.06 | $5.4M | 440,345 | Dec 1, 2025 |
| Nov 26, 2025 | SOpen-market sale Ordinary Shares | -8,380 | $179.23 | $1.5M | 431,965 | Dec 1, 2025 |
| Nov 26, 2025 | SOpen-market sale Ordinary Shares | -507 | $179.79 | $91k | 431,458 | Dec 1, 2025 |
| Nov 26, 2025 | SOpen-market sale Ordinary Shares | -38,126 | $177.27 | $6.8M | 393,332 | Dec 1, 2025 |
| Nov 26, 2025 | MOption exercise Incentive Stock Option (right to buy)derivative | -811 | $0.00 | $0 | 0 | Dec 1, 2025 |
| Nov 26, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative | -76,689 | $0.00 | $0 | 0 | Dec 1, 2025 |
Related signals
Other insiders at Jazz Pharmaceuticals plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Jazz Pharmaceuticals plc | Renee D Gala President & CEO | $473k 2,000 shares | -1% | |
| 28Weak | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.4M 6,000 shares | -2% | |
| 24Weak | Jazz Pharmaceuticals plc | Neena M Patil EVP & Chief Legal Officer | $289k 1,200 shares | -2% | |
| 38Weak | Jazz Pharmaceuticals plc | Renee D Gala President & CEO | $486k 2,000 shares | -1% | |
| 45Moderate | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.5M 6,000 shares | -2% | |
| 51Moderate | Jazz Pharmaceuticals plc | Mary Elizabeth Henderson SVP, Technical Operations | $379k 2,238 shares | -10% | |
| 57Moderate | Jazz Pharmaceuticals plc | Patricia Carr SVP, Chief Accounting Officer | $798k 4,660 shares | -65% | |
| 39Weak | Jazz Pharmaceuticals plc | Heather Ann McSharry director | $607k 3,415 shares | -14% | |
| 55Moderate | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $3.3M 18,000 shares | -4% | |
| 60Notable | Jazz Pharmaceuticals plc | Patricia Carr SVP, Chief Accounting Officer | $968k 5,319 shares | -75% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.